Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Core Viewpoint - Surrozen, Inc. has announced a strategic research collaboration with TCGFB, Inc. to develop antibody therapeutics targeting TGF-β for the treatment of idiopathic pulmonary fibrosis (IPF) [1][4]. Group 1: Collaboration Details - Surrozen will provide antibody discovery services for up to two years, with TCGFB owning all related intellectual property [2]. - TCGFB will compensate Surrozen with up to $6 million and issue warrants for up to 3,380,000 shares of TCGFB common stock at an exercise price of$0.0001 per share, contingent on certain vesting conditions [2]. Group 2: Company Background - Surrozen is a clinical-stage biotechnology company focused on discovering and developing drug candidates that selectively modulate the Wnt pathway, with a current emphasis on severe liver and eye diseases [3]. - TCGFB is a biotechnology company founded by The Column Group, concentrating on novel antibodies targeting TGF-β for IPF treatment [4]. Group 3: Leadership Statement - Craig Parker, President and CEO of Surrozen, expressed enthusiasm for the collaboration, highlighting the potential of targeting TGF-β as a novel therapeutic approach for IPF [3].